ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
DiagnosesAntinuclear Antibody Positive

Antinuclear Antibody Positive

ICD-10 Coding for Antinuclear Antibody Positive(R76.0, R76.8)

PRIMARY SPECIALTYRheumatology
COMPLEXITYHigh
LAST UPDATED09/15/2025
Sam Tuffun, PT, DPT
Physical Therapist | Medical Coding & Billing Contributor

Diagnosis Overview

What is Antinuclear Antibody Positive?
Essential facts and insights about Antinuclear Antibody Positive

Key Clinical Considerations:

  • Presence of specific autoimmune symptoms such as fatigue, joint pain, or skin rashes.
  • Positive antinuclear antibody (ANA) test results, typically with a titer of 1:40 or higher.
  • Physical examination may reveal signs of systemic lupus erythematosus (SLE) or other autoimmune disorders.
  • Imaging studies may show joint inflammation or damage in cases of associated rheumatic diseases.
  • Severity criteria may include the extent of organ involvement or the presence of specific autoantibodies.

Clinical Information

Clinical Criteria & Documentation Requirements

  • Complete medical history including symptoms, duration, and impact on daily activities.
  • Specific terminology such as 'positive ANA' and any associated autoimmune conditions.
  • Examples include documenting the ANA titer, specific symptoms, and any relevant family history.
  • Medical necessity must be established through documentation of symptoms and clinical rationale for testing.
  • Quality measures may include tracking the frequency of follow-up visits and laboratory monitoring.

Coding Guidelines

Usage Guidelines & Examples

  • Use this diagnosis code when a patient presents with positive ANA and related symptoms.
  • Do not use this code for patients with negative ANA results or those without autoimmune symptoms.
  • Similar codes include R76.8 for other abnormal immunological findings; differentiate based on specific test results.
  • Common errors include coding without adequate documentation of symptoms or misinterpreting ANA results.
  • In complex cases, consider additional codes for specific autoimmune diseases or related conditions.

Code Exclusions

Important Exclusions

  • Conditions such as drug-induced lupus or infections that may cause false-positive ANA results.
  • Alternative codes for excluded conditions include T88.1 for adverse effects of drugs and B20 for HIV-related conditions.
  • Exclusions are based on the need for accurate diagnosis and treatment planning; misdiagnosis can lead to inappropriate management.
  • Common mistakes include failing to document the context of the positive ANA or not ruling out other conditions.
  • Related but distinct conditions include antiphospholipid syndrome and other autoimmune diseases that may present similarly.

Related ICD-10 Codes

Primary Codes
R76.0
Antinuclear antibody positive
R76.8
Other abnormal immunological findings
Differential Codes
R76.8
R76.8
for specific ANA patterns like speckled or homogeneous.
R76.0
R76.0
for elevated titers without specific patterns.

Related CPT Codes

CPT codes will be available in a future update.

Specialty Focus

Primary Specialty

Rheumatology

Specialty Applications

  • Applies to conditions such as systemic lupus erythematosus, rheumatoid arthritis, and mixed connective tissue disease.
  • Patient populations include adults, particularly women aged 20-50, who are at higher risk for autoimmune diseases.
  • Clinical settings include outpatient rheumatology clinics, inpatient hospital settings, and emergency departments.
  • Specialty-specific applications are primarily in rheumatology but may also involve immunology and primary care.
  • Treatment contexts include initial diagnosis, ongoing management of autoimmune conditions, and monitoring of disease activity.

Coding Complexity

High Complexity

This diagnosis requires careful attention to:

  • Comprehensive clinical documentation
  • Accurate code selection based on clinical criteria
  • Proper exclusion considerations
  • Specialty-specific coding guidelines

Documentation

Documentation Templates

Template 1

Template: 'Patient diagnosed with positive ANA based on clinical findings of fatigue and joint pain.'

Template 2

Template: 'Clinical presentation consistent with autoimmune disorder including rash and arthralgia.'

Template 3

Template: 'Diagnostic criteria for autoimmune disease met as evidenced by positive ANA and specific symptoms.'

Template 4

Template: 'Treatment plan initiated for autoimmune condition with corticosteroids and immunosuppressants.'

Template 5

Template: 'Follow-up care for positive ANA including monitoring of symptoms and laboratory parameters.'

Billing Information

Billing Considerations

  • Ensure proper documentation for billing
  • Verify code specificity requirements
  • Check for any additional codes needed
  • Review payer-specific guidelines

Common Issues

  • Insufficient clinical documentation
  • Incorrect code selection
  • Missing supporting diagnoses
  • Timing and frequency documentation

Frequently Asked Questions

What documentation is required for this diagnosis?

Detailed documentation of symptoms, laboratory results, and clinical findings is essential.

How does this differ from similar diagnoses?

Key differentiators include specific symptoms and laboratory findings that indicate autoimmune activity.

What are common billing considerations?

Ensure that documentation supports medical necessity and that all relevant codes are included for comprehensive billing.

What procedures are typically associated?

Related CPT codes may include laboratory tests for ANA and other autoimmune panels.

Are there any quality reporting implications?

Quality measures may include tracking ANA testing frequency and follow-up care for patients with positive results.